- In full:
- Sir Peter John Ratcliffe
- Born:
- May 14, 1954, Lancashire, England (age 72)
- Awards And Honors:
- Nobel Prize (2019)
Peter J. Ratcliffe
-
Who is Peter J. Ratcliffe?
Peter J. Ratcliffe, born May 14, 1954, is a British physician and scientist celebrated for his work on erythropoietin regulation and how cells sense oxygen levels. This hormone stimulates red blood cell production when blood oxygen levels are low. Ratcliffe's research revealed that cells in various organs possess oxygen-sensing capabilities, influencing processes like differentiation and metabolism.
His discoveries, made independently and with William G. Kaelin, Jr., and Gregg L. Semenza, about how cells sense oxygen, earned him a share of the 2019 Nobel Prize in Physiology or Medicine. Ratcliffe found that a modification on hypoxia-inducible factor (HIF) dictates how cells respond to changing oxygen levels, impacting key cellular processes and enabling cells to adapt to hypoxic conditions. His work significantly advanced the understanding of cancer, as tumors often thrive under low-oxygen conditions due to elevated HIF activity.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is Peter J. Ratcliffe known for in science?
Peter J. Ratcliffe is a British physician and scientist notable for his research on erythropoietin regulation, a hormone that boosts red blood cell production when oxygen levels are low, and for his investigations into how cells detect oxygen.
His discoveries concerning cellular oxygen-sensing mechanisms earned him a share of the 2019 Nobel Prize for Physiology or Medicine with William G. Kaelin, Jr., and Gregg L. Semenza. Ratcliffe's work revealed that cells in multiple organs possess oxygen-sensing capabilities and that cellular responses to oxygen availability impact processes such as cell differentiation and metabolism.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What important discovery did Peter J. Ratcliffe help make about how cells sense oxygen?
Peter J. Ratcliffe's research into erythropoietin regulation led to the important discovery that cells in multiple organs possess oxygen-sensing abilities. Ratcliffe, along with William G. Kaelin, Jr., discovered that prolyl hydroxylation on hypoxia-inducible factor (HIF) dictates how cells respond to changing oxygen levels. When this modification is present, HIF is marked for degradation, but when absent, HIF persists, altering cellular processes to facilitate adaptation to hypoxic conditions. These findings significantly impacted the understanding of cancer, as tumors often thrive under hypoxic conditions due to elevated HIF activity.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
Why is understanding how cells detect oxygen important for medicine?
Understanding how cells detect oxygen, a field pioneered by Peter J. Ratcliffe, is crucial for medicine because it reveals how cells adapt to hypoxia, or oxygen deprivation. Ratcliffe's research showed that cells in multiple organs possess oxygen-sensing abilities, impacting processes like cell differentiation and metabolism.
His work, which earned him a share of the 2019 Nobel Prize, demonstrated that a molecule called hypoxia-inducible factor (HIF) is modified based on oxygen levels, dictating cellular responses. When oxygen is low, HIF persists, enabling cells to survive; this is particularly significant in cancer, where tumors thrive under hypoxic conditions due to elevated HIF activity. Thus, understanding these mechanisms allows for the development of drugs that target HIF, slowing tumor growth and offering potential cancer treatments.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What awards has Peter J. Ratcliffe received for his work?
Peter J. Ratcliffe is a British physician and scientist notable for his research on erythropoietin regulation and cellular oxygen-sensing mechanisms.
Ratcliffe's awards include:
* 2019 Nobel Prize for Physiology or Medicine (shared with William G. Kaelin, Jr., and Gregg L. Semenza)
* 2016 Albert Lasker Basic Medical Research Award (shared with Kaelin and Semenza)
* 2014 Knighthood
* 2010 Canada Gairdner International Award
* 2002 Election to the Royal Society1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How could Peter J. Ratcliffe’s research help treat diseases in the future?
Peter J. Ratcliffe's research into how cells sense and respond to low oxygen levels (hypoxia) could lead to future treatments for diseases like cancer and anemia. His work revealed that cells in various organs have oxygen-sensing abilities, impacting processes like cell differentiation and metabolism.
Ratcliffe discovered that a molecule called hypoxia-inducible factor (HIF) is critical for how cells adapt to changes in oxygen levels. Tumors often thrive under hypoxic conditions due to elevated HIF activity, so understanding this process is especially significant for cancer research. Some anticancer drugs that target HIF have already shown success in slowing or halting tumor growth.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Peter J. Ratcliffe (born May 14, 1954, Lancashire, England) is a British physician and scientist known for his research into the regulation of erythropoietin, a hormone that stimulates red blood cell production in response to low blood oxygen levels, and for his research into the mechanisms cells use to sense oxygen. His discoveries pertaining to cellular oxygen-sensing mechanisms earned him a share of the 2019 Nobel Prize for Physiology or Medicine (shared with American scientists William G. Kaelin, Jr., and Gregg L. Semenza).
Ratcliffe attended Lancaster Royal Grammar School from 1965 to 1971 and later studied medicine at Gonville & Caius College, Cambridge. In 1978 he completed bachelor’s degrees in medicine and surgery at St. Bartholomew’s Hospital in London, and in 1987 he graduated from Cambridge with a medical degree. He subsequently went to the University of Oxford to study renal medicine with a particular interest in oxygen delivery to renal tissues. In 1989 he established a laboratory at Oxford in order to focus his research specifically on cellular oxygen-sensing pathways and erythropoietin regulation. From 2004 to 2016 he served as head of the Nuffield Department of Medicine at Oxford. In 2016 he was appointed director of Oxford’s Target Discovery Institute and clinical research director at the Francis Crick Institute, London.
In the late 1980s and early 1990s, when Ratcliffe was starting his research, it was known that erythropoeitin is produced by kidney cells when blood oxygen levels are reduced. However, Ratcliffe’s investigations of erythropoeitin production led to the realization that cells in multiple other organs, including the brain and the liver, also are equipped with oxygen-sensing abilties. He also found that cellular responses to oxygen availability affect other processes in cells, such as differentiation and metabolism. In particular, Ratcliffe and Kaelin, working independently, discovered that a chemical modification known as prolyl hydroxylation on a molecule called hypoxia-inducible factor (HIF) dictates how cells respond to changes in oxygen levels. When the modification is present, HIF is marked for degradation. When absent, HIF persists, and key cellular processes are altered to facilitate adaptation to hypoxic conditions, thereby enabling cells to continue to grow and replicate. The findings were especially significant for their impact on scientists’ understanding of cancer: tumours often thrive under hypoxic conditions, which is in large part due to elevated HIF activity.
In addition to receiving the Nobel Prize, Ratcliffe was honoured with various other awards during his career. In 2010 he received the Canada Gairdner International Award, and in 2016 he shared the Albert Lasker Basic Medical Research Award with Kaelin and Semenza. He was elected to the Royal Society in 2002 and was knighted in 2014.